학술논문
Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study
Document Type
Article
Source
In Lung Cancer October 2021 160:111-117
Subject
Language
ISSN
0169-5002